Background: We have previously shown that flavonoids such as luteolin, apigenin and fisetin inhibit interleukin 4 and interleukin 13 production. In this study, we investigated whether luteolin can suppress CD40 ligand expression by basophils. Methods: A human basophilic cell line, KU812, was stimulated with A23187 and phorbol myristate acetate (PMA) with or without various concentrations of luteolin or other flavonoids for 12 h, and CD40 ligand expression was analyzed by FACS. The effect of luteolin on CD40 ligand mRNA expression was studied by semiquantitative reverse transcription PCR analysis. In addition, CD40 ligand expression was also measured in purified basophils that had been stimulated for 12 h with A23187 plus PMA with or without various concentrations of luteolin. Results: CD40 ligand expression by KU812 cells was enhanced noticeably in response to A23187 and even more strikingly augmented by A23187 plus PMA. The expression was significantly suppressed by 10 or 30 µM of luteolin, whereas myricetin failed to inhibit. Reverse transcription PCR analyses demonstrated that luteolin inhibited CD40 ligand mRNA expression by stimulated KU812 cells. Of the six flavonoids examined, luteolin, apigenin, fisetin and quercetin at 30 µM showed a significant inhibitory effect on CD40 ligand expression. The incubation of purified basophils with A23187 plus PMA significantly enhanced CD40 ligand expression, and the presence of luteolin again had an inhibitory effect. Conclusions: Luteolin inhibits CD40 ligand expression by activated basophils.

1.
Nolte H, Backer V, Porsbjerg C: Environmental factors as a cause for the increase in allergic disease. Ann Allergy Asthma Immunol 2001;87:S7–S11.
2.
Devereux G, Seaton A: Diet as a risk factor for atopy and asthma. J Allergy Clin Immunol 2005;115:1109–1117.
3.
Harborne JB, Williams CA: Advance in flavonoid research since 1992. Phytochemistry 2000;55:481–504.
4.
Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Suemura M, Kawase I, Tanaka T: Fisetin, a flavonol, inhibits T helper 2 (Th2) type cytokine production by activated human basophils. J Allergy Clin Immunol 2003;111:1299–1306.
5.
Hirano T, Higa S, Arimitsu J, Naka T, Shima Y, Ohshima S, Fujimoto M, Yamadori T, Kawase I, Tanaka T: Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int Arch Allergy Immunol 2004;134:135–140.
6.
Fewtrell CM, Gomperts BD: Effect of flavone inhibitors of transport ATPases on histamine secretion from rat mast cells. Nature 1977;265:635–636.
7.
Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486–S494.
8.
Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CMM, Tsai M: Mast cells as ‘tunable’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749–786.
9.
Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores RL, Thompson J, Kishi K, Butterfield J, Dahinden C, Bonnefoy JY: Induction of human IgE synthesis by mast cells and basophils. Nature 1993;365:340–343.
10.
Kishi K: A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res1985;9:381–390.
11.
Haisch K, Gibbs BF, Korber H, Ernst M, Grage-Griebenow E, Schlaak M, Haas H: Purification of morphologically and functionally intact human basophils to near homogeneity. J Immunol Methods 1999;226:129–137.
12.
Yanagihara Y, Kajiwara K, Basaki Y, Ikizawa K, Akiyama K, Saito H: Induction of human IgE synthesis in B cells by a basophilic cell line, KU812. Clin Exp Immunol 1997;108:295–301.
13.
Tanaka T, Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Kawase I: Flavonoids as potential anti-allergic substances. Curr Med Chem – Anti-Inflammtory Anti-Allergy Agents 2003;2:57–65.
14.
Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Anderson S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992;11:4313–4321.
15.
Verelli D: The regulation of IgE synthesis. Clin Allergy Immunol 2002;16:179–196.
16.
Etzioni A, Ochs HD: The hyper IgM syndrome – an evolving story. Pediatr Res 2004;56:519–525.
17.
Nusslein HG, Frosch KH, Woith W, Lane P, Kalden JR, Manger B: Increase of intracellular calcium is the essential signal for the expression of CD40 ligand. Eur J Immunol 1996;26:846–850.
18.
Fuleihan R, Ramesh N, Horner A, Ahern D, Belshaw PJ, Alberg DG, Stamenkovic I, Harmon W, Geha RS: Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Invest 1994;93:1315–1320.
19.
Macian F, Lopez-Rodriguez C, Rao A: Partners in transcription: NFAT and AP-1. Oncogene 2001;20:2476–2489.
20.
Cirillo R, Triggiani M, Siri L, Ciccarelli A, Pettit GR, Condorelli M, Marone G: Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990;144:3891–3897.
21.
Marone G, Spadaro G, DeMarino V, Aliperta M, Triggiani M: Immunopharmacology of human mast cells and basophils. Int J Clin Lab Res 1998;28:12–22.
22.
Plath KE, Grabbe J, Gibbs BF: Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils. Clin Exp Allergy 2003;33:342–350.
23.
Williams RJ, Spencer JPE, Rice-Evans C: Flavonoids: antioxidants or signaling molecules? Free Radic Biol Med 2002;36:838–849.
24.
Nishino H, Naito E, Iwashima A, Tanaka K, Matsuura T, Fujiki H Sugimura T: Interaction between quercetin and Ca2+-calmodulin complex: possible mechanism for anti-tumor-promoting action of the flavonoid. Gann 1984;75:311–316.
25.
Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H: Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000;30:501–508.
26.
Shichijo M, Yamamoto N, Tsujishita H, Kimata M, Nagai H, Kokubo T: Inhibition of syk activity and degranulation of human mast cells by flavonoids. Biol Pharm Bull 2003;26:1685–1690.
27.
Yano S, Tachibana H, Yamada K: Flavones suppress the expression of the high-affinity IgE receptor FcυRI in human basophilic KU812 cells. J Agric Food Chem 2005;53:1812–1817.
28.
Kotani M, Matsumoto M, Fujita A, Higa S, Wang W, Suemura M, Kishimoto T, Tanaka T: Persimmon leaf extract and astragalin inhibit development of dermatitis and IgE elevation in NC/Nga mice. J Allergy Clin Immunol 2000;106:159–166.
29.
Matsumoto M, Kotani M, Fujita A, Higa S, Kishimoto T, Suemura M, Tanaka T: Oral administration of persimmon leaf extract ameliorates skin symptoms and transepidermal water loss in atopic dermatitis model mice, NC/Nga. Brit J Dermatol 2002;146:221–227.
30.
Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A: Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002;76:560–568.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.